References
1 Based on the SURMOUNT-1 phase 3 RCT (Jastreboff et al., 2022 - DOI: 10.1056/NEJMoa2206038), conducted alongside a lifestyle intervention. Results represent estimated outcomes at the 15mg dose based on full adherence, in a clinical trial population; individual results will vary.
2 Based on the STEP UP phase 3b RCT (Wharton et al., 2025 - DOI: 10.1016/S2213-8587(25)00226-8), conducted alongside a lifestyle intervention. Results represent estimated outcomes based on full adherence, in a clinical trial population; individual results will vary.
3 Based on the OASIS 4 phase 3 RCT (Wharton et al., 2025 - DOI: 10.1056/NEJMoa2500969), conducted alongside a lifestyle intervention. Results represent estimated outcomes based on full adherence, in a clinical trial population; individual results will vary.
4 Based on the ATTAIN-1 phase 3 RCT (Wharton et al., 2025; DOI: 10.1056/NEJMoa2511774), conducted alongside a lifestyle intervention. Results represent estimated outcomes based on full adherence, in a clinical trial population; individual results will vary.
5 Based on a randomised controlled trial (Rössner S, et al. 2000 - DOI: 10.1038/oby.2000.8), conducted alongside a lifestyle intervention. Individual results will vary.
6 Griffiths, et al. Impact of Engagement on Weight Loss Outcomes with Tirzepatide and a Digital Health Programme. Conference abstract. Obesity Week. 2025.
7 Tirzepatide for managing overweight and obesity. NICE. [accessed 31 Mar 2026] Available from: https://www.nice.org.uk/guidance/ta1026
8 Semaglutide for managing overweight and obesity. NICE. [accessed 31 Mar 2026] Available from: https://www.nice.org.uk/guidance/ta875